$1.600
0.000 (0.00%)At close
IMNN News
IMNN Events
IMUNON CEO Says IMNN-001 Study Progressing Well
"The second quarter brought continued momentum for IMNN-001," said Stacy Lindborg, President and Chief Executive Officer of IMUNON. "Enrollment in our pivotal Phase 3 OVATION 3 study continues to exceed our planning assumptions, reflecting the compelling survival data generated in OVATION 2, our highly favorable safety profile, and growing confidence among investigators in IMNN-001's potential to improve outcomes for women with newly diagnosed advanced ovarian cancer."
Imunon Updates Progress on Phase 3 Trial of IMNN-001
Imunon provided a progress update on its Phase 3 OVATION 3 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer. Since initiating the trial, the company has observed rapid site activation and an enrollment rate that is exceeding its forecast. The trial advanced from protocol submission to site activation in approximately six months and from protocol approval to first patient randomized in approximately two months, a third of the time of the external industry benchmark.
Imunon Announces Preliminary Data from IMNN-001 Clinical Trial
Imunon announced new preliminary data from its ongoing Phase 2 minimal residual disease, or MRD, translational clinical trial of IMNN-001, conducted in combination with standard of care neoadjuvant and adjuvant chemotherapy plus bevacizumab, in women with newly diagnosed advanced ovarian cancer. This translational study is being conducted through the Break Through Cancer Targeting Minimal Residual Disease in Ovarian Cancer TeamLab, a multi-institutional collaboration accelerating research in ovarian cancer. The multi-site study is led by investigators at The University of Texas MD Anderson Cancer Center, which serves as the lead clinical site. Its objectives include understanding how chemo-immunotherapy with IMNN-001 impacts ovarian cancer's "cold" tumor microenvironment and MRD after frontline treatment. Nine patients in each of the control and experimental arms have reached second-look laparoscopy, the study's primary assessment point for surgical MRD. Compared to control, preliminary results show a deeper antitumor response, as demonstrated by a lower MRD-positive rate, in patients treated with IMNN-001, a higher rate of circulating tumor DNA, and a numerically higher rate of patients achieving no evidence of disease following frontline therapy.
Imunon Appoints Josh Blacher as New Interim CFO
In a regulatory filing, the company stated, "On June 29, 2026, Jeffrey Church informed Imunon of his intent to retire from the position of interim Chief Financial Officer, a position he has held since January of 2026, effective July 1, 2026. To help ensure a smooth transition of his responsibilities to his successor, Church and the company agreed that he will continue in a consulting role with the company. As a result of Mr. Church's retirement, effective July 1, 2026, the company appointed Josh Blacher to serve as the company's new interim Chief Financial Officer under a master services agreement, dated June 24, 2026, between the company and Danforth Health, Inc., a financial advisory services firm. Mr. Blacher will serve as the company's principal financial officer and principal accounting officer."
Imunon OVATION 3 Clinical Trial Continues
Imunon announced that the independent Data Monitoring Committee, or IDMC, has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy in women with newly diagnosed advanced ovarian cancer. "We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer," said Stacy Lindborg, president and chief executive officer of Imunon. "We remain ahead of our anticipated schedule in patient enrollment and this recommendation by the iDMC brings new levels of momentum to our efforts to advance this trial as rapidly as possible."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.